Trastuzumab deruxtecan

Generic Name: Trastuzumab deruxtecan

Brand Names: Enhertu

Drug Type: Biotech

Chemical Formula: -

CAS Number: 1826843-81-5

Unique Ingredient Identifier: 5384HK7574

Background: Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...

Indication: In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...

Associated Conditions: Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer

Associated Therapies: -

Clinical Trials

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Phase 3

Not yet recruiting

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Trastuzumab Deruxtecan
Drug: Pembrolizumab
Drug: Trastuzumab
Drug: Chemotherapy

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 726

Registration Number: NCT06731478

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Phase 2

Not yet recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Trastuzumab deruxtecan
Drug: Capecitabine
Drug: Rilvegostomig

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-16

Lead Sponsor: Jeeyun Lee

Target Recruit Count: 50

Registration Number: NCT06630130

Castrate Resistant Prostate Cancer Enhertu Therapy

Phase 2

Not yet recruiting

Conditions: Prostate Cancer Metastatic
Prostate Cancer
CRPC

Interventions: Drug: Enhertu

First Posted Date: 2024-09-24

Last Posted Date: 2024-09-24

Lead Sponsor: Washington D.C. Veterans Affairs Medical Center

Target Recruit Count: 60

Registration Number: NCT06610825

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab Deruxtecan

First Posted Date: 2024-08-13

Last Posted Date: 2024-12-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 800

Registration Number: NCT06551220

Locations: 🇨🇳
Fujian Cancer Hospital, Fujian Medical University, Fuzhou, Fujian, China
🇨🇳
The 10th Affiliated Hospital of Southern Medical University, Dongguan, Guangdong, China
🇨🇳
The First People's Hospital of Foshan, Foshan, Guangdong, China

and more 20 locations